Owlstone Medical ('Owlstone') is the global leader in Breath Biopsy® for applications in early disease detection and precision medicine. The first closing of US$27 million in its Series E financing round was led by Ventura Capital and joined by investors including Aviva Ventures, the Gates Foundation and Horizons Ventures.

The funds raised will be used to support the clinical development of a breath test for the early detection of lung cancer and to accelerate commercialisation of diagnostic tests and point-of-care devices for liver disease and digestive disease.

The Broadfield team was led by Cambridge Corporate Finance Partner Duncan Walker, who said: